Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma

LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

(2022) Maria-Victoria Mateos et al.   LEUKEMIA

Teclistamab in Relapsed or Refractory Multiple Myeloma

(2022) Philippe Moreau et al.   NEW ENGLAND JOURNAL OF MEDICINE

Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1

(2022) Ajai Chari et al.   BLOOD

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

(2021) Nikhil C. Munshi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial

(2021) Martin Hutchings et al.   JOURNAL OF CLINICAL ONCOLOGY

Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma

(2021) Christie P. M. Verkleij et al.   Blood Advances

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study

(2021) Martin Hutchings et al.   LANCET

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

(2021) Jesus G Berdeja et al.   LANCET

Mathematical Models of Blood-Brain Barrier Transport of Monoclonal Antibodies Targeting the Transferrin Receptor and the Insulin Receptor

(2021) William M. Pardridge et al.   Pharmaceuticals

Phase I First-in-Class Trial of MCARH109, a G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D) Targeted CAR T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma

(2021) Sham Mailankody et al.   BLOOD

A T CELL REDIRECTING BISPECIFIC G-PROTEIN COUPLED RECEPTOR CLASS 5 MEMBER DxCD3 ANTIBODY TO TREAT MULTIPLE MYELOMA

(2020) Kodandaram Pillarisetti et al.   BLOOD

The GTEx Consortium atlas of genetic regulatory effects across human tissues

(2020)   SCIENCE

GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells

(2019) Eric L. Smith et al.   Science Translational Medicine

Anti-GPRC5D/CD3 bispecific T cell-redirecting antibody for the treatment of multiple myeloma

(2019) Tatsushi Kodama et al.   MOLECULAR CANCER THERAPEUTICS

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

(2019) Ajai Chari et al.   NEW ENGLAND JOURNAL OF MEDICINE

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

(2019) Sagar Lonial et al.   LANCET ONCOLOGY

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

(2017) S K Kumar et al.   LEUKEMIA

Multiple myeloma

(2017) Shaji K. Kumar et al.   Nature Reviews Disease Primers

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

(2016) Sagar Lonial et al.   LANCET

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

(2015) Sagar Lonial et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

(2015) Henk M. Lokhorst et al.   NEW ENGLAND JOURNAL OF MEDICINE

Current concepts in the diagnosis and management of cytokine release syndrome

(2014) D. W. Lee et al.   BLOOD

GPRC5D is a promising marker for monitoring the tumor load and to target multiple myeloma cells

(2013) Yossi Cohen et al.   Hematology

Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma

(2012) Johanna Atamaniuk et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

(2011) S. V. Rajkumar et al.   BLOOD

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

(2011) S K Kumar et al.   LEUKEMIA

Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma

(2008) Antonio Palumbo et al.   BLOOD REVIEWS

Critical aspects of the Bayesian approach to phase I cancer trials

(2008) Beat Neuenschwander et al.   STATISTICS IN MEDICINE